c-Myc in breast cancer

Endocrine-Related Cancer

Volumn 7, Issue 3, 2000, Pages 143-164

  Liao, D J ^a   Dickson, R B ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROGESTERONE RECEPTOR;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE C MYC; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 0033790685     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070143     Document Type: Review

References (278)

1. Proto-oncogene amplification and human breast tumor phenotype
2. Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis
3. Modulation of c-Myc activity and apoptosis in vivo
4. c-Myc-enhanced S phase entry in keratinocytes is associated with positive and negative effects on cyclin-dependent kinases
5. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity
6. Myc and the cell cycle
7. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis
8. Transgenic mouse models of breast cancer
9. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis
10. Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines
11. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: A frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial
12. Prognostic significance of TGF-alpha expression in breast cancer
13. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer
14. Cyclin D1 in breast cancer
15. c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression
16. Cyclin A links c-Myc to adhesion-independent cell proliferation
17. Interactions of the nuclear matrix-associated steroid receptor binding factor with its DNA binding element in the c-myc gene promoter
18. Testosterone treatment of women
19. Androgen replacement for women
20. Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately
21. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
22. Involvement of Myc targets in c-myc and N-myc induced human tumors
23. Sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors
24. c-Myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer
25. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors
26. Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification
27. Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival
28. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
29. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
30. Serum sex hormone levels after menopause and subsequent breast cancer
31. A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer
32. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay
33. Retroviruses and cancer genes
34. Structure and expression of oncogenes in surgical specimens of human breast carcinomas
35. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma
36. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: Contrasting effects of homozygous and heterozygous p53 loss
37. Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer
38. In vivo amplification and rearrangement of c-myc oncogene in human breast tumors
39. Somatostatin receptor-positive primary breast tumors: Genetic, patient and tumor characteristics
40. c-Myc amplification is an independent prognostic factor in postmenopausal breast cancer
41. Control of cell proliferation by Myc
42. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients
43. A flow cytometric study of c-erbB-3 expression in breast cancer
44. Comparative pathology of mammary tumorigenesis in transgenic mice
45. The comparative pathology of human and mouse mammary glands
46. Transgenic oncogene mice. Tumor phenotype predicts genotype
47. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting
48. Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1
49. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of the Osteoporotic Fractures Research Group
50. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer
51. Oncogene amplification per se: An independent prognostic factor in human breast cancer
52. The prognostic significance of c-myc oncogene expression in uveal melanoma
53. c-Myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma
54. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals
55. c-Myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
56. Myc-mediated transformation: The repression connection
57. Progestin regulation of cellular proliferation
58. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop
59. Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease
60. The Myc oncoprotein: A critical evaluation of transactivation and target gene regulation
61. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
62. Liver regeneration versus direct hyperplasia
63. Different effects of regenerative and direct mitogenic stimuli on the growth of initiated cells in the resistant hepatocyte model
64. High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers
65. Expression of the multidrug-resistance (MDR) gene in breast cancer
66. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation
67. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification
68. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups
69. Prolactin activates protein kinase C and stimulates growth-related gene expression in rat liver
70. Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations
71. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle
72. c-Myc target genes involved in cell growth, apoptosis, and metabolism
73. Function of the c-Myc oncogenic transcription factor
74. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms
75. c-Myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance
76. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation
77. The multiple role of PTEN in tumor suppression
78. Growth factors in breast cancer
79. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlatioh with p53 and bcl-2 expression, proliferative activity and prognosis
80. Histogenetic and morphological in vivo and in vitro data concerning androgen-estrogen-induced scent gland tumor in the Syrian hamster
81. Regulation of p27Kip1 accumulation in murine B-lymphoma cells: Role of c-myc and calcium
82. Mechanism of estrogen activation of c-myc oncogene expression
83. Cell growth: Downstream of Myc - To grow or to cycle?
84. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms
85. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice
86. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas
87. Computer-aided quantification of RNA levels detected by in situ hybridization of tissue sections
88. Potential value of increased MYC but not ERBB2 RNA levels as a marker of high-risk mastopathies
89. Induction of apoptosis in fibroblasts by c-myc protein
90. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights
91. Transient excess of MYC activity can elicit genomic instability and tumorigenesis
92. Rapid regulation of c-myc protooncogene expression by progesterone in the avian oviduct
93. The prognostic value of tumor-associated carbohydrate structures correlated with gene amplifications in human breast carcinomas
94. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: Clinicopathologic correlations
95. c-Myc promotes differentiation of human epidermal stem cells
96. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas
97. The c-myc oncogene in tumor progression
98. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation
99. Cyclin D1 and prognosis in human breast cancer
100. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma
101. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA
102. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation
103. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: Correlation with poor prognosis
104. Strong association between c-myb and oestrogen-receptor expression in human breast cancer
105. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1
106. Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: Frequency and clinical significance
107. Signaling through the antigen receptor of B lymphocytes activates a p53-independent pathway of c-Myc-induced apoptosis
108. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations
109. Clinical implication of altered expression of Mad1 protein in human breast carcinoma
110. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women
111. Estrogen and progesterone receptors in mammary tumors induced in rats by simultaneous administration of 17 beta-estradiol and progesterone
112. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations
113. c-Myc oncogene expression: A marker for females at risk of breast carcinoma
114. Hormonal carcinogenesis
115. Proteins of the Myc network: Essential regulators of cell growth and differentiation
116. Int-2 amplification in breast cancer: Association with decreased survival and relationship to amplification of c-erbB-2 and c-myc
117. Identification of CDK4 as a target of c-MYC
118. The use of androgens in menopause
119. The proto-oncogene c-myc and apoptosis
120. Transforming growth factor alpha and mouse models of human breast cancer
121. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors
122. Steroid hormone-induced expression of oncogene encoded nuclear proteins
123. c-Myc enhances protein synthesis and cell size during B lymphocyte development
124. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer
125. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice
126. Assessing sequential oncogene amplification in human breast cancer
127. Differential modulation of cyclin gene expression by MYC
128. Drosophila myc regulates cellular growth during development
129. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer
130. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells
131. Hormone-related tumors in Syrian hamsters
132. Autonomous variants of an androgen/estrogen-induced and -dependent ductus deferens leiomyosarcoma of the Syrian hamster
133. Characteristics of an androgen-estrogen-induced uterine smooth muscle cell tumor of the Syrian hamster
134. Molecular action of androgen in the normal and neoplastic prostate
135. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
136. Tissue microarrays for high-throughput molecular profiling of tumor specimens
137. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer
138. Estrogen activates telomerase
139. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)
140. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice
141. c-Myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients
142. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer
143. Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: Role of c-myc and bcl-2 in apoptotic cell death
144. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast
145. Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: Probable mediation by steroid receptors
146. Cell cycle basis for the onset and progression of c-Myc-induced. TGFalpha-enhanced mouse mammary gland carcinogenesis
147. Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression
148. Benign breast disease: Absence of genetic alterations at several loci implicated in breast cancer malignancy
149. c-Myc oncogene product expression and prognosis in operable breast cancer
150. c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts
151. Prognostic value of erb-B2 and myc amplification in breast cancer imprints
152. Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features
153. Apoptosis in cancer
154. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability
155. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer
156. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins
157. Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase
158. Genomic instability in MycER-activated Rat1 A-MycER cells
159. Myc represses the growth arrest gene gadd45
160. In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast
161. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas
162. C-myc gene chromatin of estrogen receptor-positive and -negative breast cancer cells
163. Expression of ornithine decarboxylase mRNA and c-myc mRNA in breast tumours
164. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells
165. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas
166. A sequence in the 5' flanking region confers progestin responsiveness on the human c-myc gene
167. Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors
168. Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma
169. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
170. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes
171. Mechanisms of cyclin-dependent kinase inactivation by progestins
172. Estrogen and progesterone receptor mRNA levels in primary breast cancer: Association with patient survival and other clinical and tumor features
173. Analysis of genetic alterations related to the development and progression of breast carcinoma
174. Defining a role for c-Myc in breast tumorigenesis
175. MYC oncogenes and human neoplastic disease
176. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status
177. Cyclin E expression and proliferation in breast cancer
178. Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia
179. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer
180. Mysterious liaisons: The relationship between c-Myc and the cell cycle
181. In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells
182. Identification of Mad as a repressor of the human telomerase (hTERT) gene
183. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
184. c-Myc and apoptosis
185. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues
186. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer
187. Evaluation of c-myc proto-oncogene in primary human breast carcinomas
188. c-Myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma
189. Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast
190. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes
191. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1)
192. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
193. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer
194. Repression of cyclin D1: A novel function of MYC
195. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival
196. C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: Immunohistochemical study correlated with malignancy
197. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
198. Mechanisms of apoptosis by c-Myc
199. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide
200. Comparative polymerase chain reaction analysis of c-myc amplification on archival breast fine-needle aspiration materials
201. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas
202. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice
203. c-Myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse
204. Cellular localisation of c-myc product in human colorectal epithelial neoplasia
205. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy
206. Myc oncogenes: The enigmatic family
207. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology
208. New Myc-interacting proteins: A second Myc network emerges
209. Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast
210. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice
211. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha
212. Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma
213. The role of c-myc in cellular growth control
214. Tissue microarrays for gene amplification surveys in many different tumor types
215. Steroid hormone regulation of nuclear proto-oncogenes
216. Control of cell growth by c-Myc in the absence of cell division
217. Determination of c-myc amplification and overexpression in breast cancer patients: Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis
218. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer
219. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals
220. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
221. Deregulated c-Myc induces alteration of DNA damage-dependent G1/S checkpoint in haman mammary epithelial cells
222. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas
223. c-Myc oncogene expression in estrogen-dependent and -independent breast cancer
224. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas
225. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer
226. Detection of the c-myc oncogene product in testicular cancer
227. c-Myc oncogene expression in colorectal cancer
228. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo
229. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene
230. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
231. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma
232. Elevated expression of the myc gene in human benign and malignant breast lesions compared with normal tissue
233. High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique
234. Ras, c-myc and c-erbB-2 oncoproteins in human breast cancer
235. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: A concomitant expression
236. An antisense promoter of the murine c-myc gene is localized within intron 2
237. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins
238. Molecular characterization of intraductal breast carcinomas
239. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
240. c-Myc reverses neu-induced transformed morphology by transcriptional repression
241. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells?
242. C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage, and histologic grade and type
243. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast iesions. With special reference to their prognostic significance in carcinoma
244. Expression of heat shock protein 70 and c-Myc protein in human breast cancer: An immunohistochemical study
245. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma
246. Immunohistochemistry, in situ hybridization and polymerase chain reaction (PCR) in detecting c-myc expression in human malignancies
247. c-Myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent
248. Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells
249. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: Hst-1/int-2 and c-erbB-2/ear-1
250. Alterations in copy number of c-erbB-2 and c-myc proto-oncogenes in advanced stage of human breast cancer
251. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride
252. Apoptosis during breast carcinoma progression
253. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
254. An unusual alteration in c-myc in tissue from a primary breast carcinoma
255. Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics
256. Prolactin: The forgotten hormone of human breast cancer
257. Prolactin involvement in breast cancer
258. Oncogene expression in cholangiocarcinoma and in normal hepatic development
259. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type
260. Targeted expression of c-Myc in the epidermis alters normal proliferation, differentiation and UV-B induced apoptosis
261. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas
262. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells
263. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer
264. Oncogene expression in ovarian cancer: A pilot study of c-myc oncoprotein in serous papillary ovarian cancer
265. Flow cytometric quantitation of the c-myc oncoprotein in archival neoplastic biopsies of the colon
266. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis
267. Differential expression of cellular oncogenes in benign and malignant human breast tissue
268. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens
269. A and B forms of thee androgen receptor are expressed in a variety of human tissues
270. Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells
271. Increased p27(Kip1) cyclin-dependent kinase inhibitor gene expression following anti-IgM treatment promotes apoptosis of WEHI 231 B cells
272. Inducible overproduction of the mouse c-myc protein in mammalian cells
273. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis
274. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17beta-oestradiol and testosterone
275. Sex hormone-induced mammary carcinogenesis in female noble rats: The role of androgens
276. Analysis of oncogenes and tumor suppressor genes in human breast cancer
277. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer
278. Regulation of expression of the messenger ribonucleic acid encoding the cytosolic form of phosphoenolpyruvate carboxykinase in liver and small intestine of lactating rats